Nasdaq · Healthcare
BIOLIFE SOLUTIONS INC (BLFS)
As-reported financials and recent SEC filings for BIOLIFE SOLUTIONS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$96.2M
Net income
$-4.6M
Net margin
-4.8%
Diluted EPS
$-0.10
ROE
-1.2%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $96.2M | $74.6M | $68.0M | $76.2M | $119.2M |
| Gross profit | $62.1M | $50.1M | $41.3M | — | — |
| Operating income | $-16.6M | $-4.5M | $-17.2M | $-5.9M | $-35.2M |
| Net income | $-4.6M | $-20.2M | $-68.0M | $-139.8M | $-8.9M |
| Diluted EPS | $-0.10 | $-0.44 | $-1.55 | $-3.25 | $-0.23 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →Largest Healthcare peers
Go deeper on BLFS
Search BIOLIFE SOLUTIONS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.